Viatris, Opus gain as FDA to review label expansion for eyecare drug
Source: SeekingAlpha
2026-02-25 08:10:21 ET
More on Viatris, Opus Genetics
- Opus Genetics: Asymmetric Upside With LCA5 And BEST1
- Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
- Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Opus Genetics higher after $25M private placement
- Viatris gains as UBS upgrades to Buy on outlook and pipeline
Read the full article on Seeking Alpha
For further details see:
Viatris, Opus gain as FDA to review label expansion for eyecare drug
Opus Genetics Inc.
NASDAQ: IRD
IRD Trading
2.38% G/L:
$5.17 Last:
714,969 Volume:
$4.77 Open:
IRD Latest News
March 10, 2026 07:00:00 am
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
IRD Stock Data
$240,685,086
64,412,570
5.97%
14
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
